15 research outputs found
Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures
The antiepileptic drug vigabatrin (VGB) is a selective irreversible inhibitor of GABA-transaminase. It is administered as a racemic R(â), S(+) mixture, but the pharmacological activity of vigabatrin resides in the S(+) enantiomer and the R(â) enantiomer is inactive. The pharmacokinetic parameters of the two enantiomers have been studied after administration of a single oral 125âmg dose of the racemate to six neonates. The mean values of Cmax and AUC of the S(+) enantiomer were significantly lower (Cmax : 14.0±4.3âmg lâ1; AUC: 143±44âmg lâ1âh) than those of the R(â) enantiomer (Cmax: 34.1±9.5âmg lâ1; AUC: 231±88âmg lâ1âh), whereas no significant difference in the time to reach Cmax (S(+): 2.1±1.1âh; R(â): 2.2±1âh) was observed between the two enantiomers. During chronic administration (125âmg twice daily over 4 days), there was no evidence of accumulation of either enantiomer
Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children
1âLamotrigine is a new antiepileptic drug, chemically unrelated to currently used antiepileptic medication. Its pharmacokinetics can be influenced by concomitant antiepileptic medication